China Kangtai Cactus Biotech Q2 Revenue Up 30% to Record $6.5M; Net Income Up 37% to $1.4M, EPS $0.07

Friday, September 18, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

HARBIN, China, Aug. 13 China Kangtai CactusBiotech Inc. (OTC Bulletin Board: CKGT), a vertically integrated grower,developer, manufacturer, and marketer of a variety of cactus-based products inChina, announced today that revenue for the second quarter of 2009 increased30% to $6.5 million from $5.0 million in the second quarter of 2008. Dilutedearnings per share for the quarter was $0.07 based on a net income of $1.4million, compared to a net income of $1.0 million or $0.06 diluted EPS lastyear.

For the first six months of 2009, revenue was $9.8 million, an increase of27% from $7.8 million for the comparable period last year. Net income for thefirst six months of 2009 was up 29% at $2.1 million, compared to $1.6 millionfor the first six months of 2008.

China Kangtai CEO Jinjiang Wang said, "The pace of our revenue growthaccelerated in the second quarter with a year-over-year increase of 30% and asequential increase of 96%. This was primarily driven by growing acceptance ofour cactus-derived products. The increase in consumer consumption, led byKangtai's expanding brand awareness, indicates a bright future for our healthand wellness products, including nutraceuticals, nutritional food and drinks,and animal feed products. We expect continued improvement throughout thesecond half of 2009 as we focus our integration efforts on the Marchacquisition to further expand our production and distribution capacity."

In March, the company acquired the assets of Qitaihe Kangwei BiotechnologyCo., Ltd. The purchase included the right to use 49,000 square meters ofstate-owned land in Qitaihe City, as well as housing, machinery, equipment,and related facilities. The purchase price was approximately $5.42 million.

About China Kangtai Cactus Biotech, Inc.

China Kangtai Cactus Biotech, Inc. is a leading grower, developer,producer, and marketer of cactus-derived products, including nutraceuticals,nutritious food, health and energy drinks, beer, wine and liquor, extracts andpowders, and animal feed. China Kangtai controls over 387 acres of plants andmaintains an active R&D group that holds 18 product patents and is seekinganother 12. China Kangtai's high-quality "green" products are sold throughoutChina via a distribution network that covers 12 of China's 23 provinces andtwo of China's four municipalities. More information may be found at or via e-mail: .

An investment profile on China Kangtai Cactus Biotech Inc. is available at . For an online investorrelations kit, visit . For more investor-relatedquestions, contact Susan Zhou, Hawk Associates, at 305-451-1888, . To subscribe to future releases via e-mail alert,visit .

This news release contains forward-looking statements as defined by thePrivate Securities Litigation Reform Act of 1995. Forward-looking statementsinclude statements concerning plans, objectives, goals, strategies, futureevents or performance, and underlying assumptions and other statements thatare other than statements of historical facts. These statements are subject touncertainties and risks including, but not limited to, product and servicedemand and acceptance, changes in technology, economic conditions, the impactof competition and pricing, government regulation, and other risks containedin reports filed by the company with the Securities and Exchange Commission.All such forward-looking statements, whether written or oral, and whether madeby or on behalf of the company, are expressly qualified by the cautionarystatements and any other cautionary statements which may accompany theforward-looking statements. In addition, the company disclaims any obligationto update any forward-looking statements to reflect events or circumstancesafter the date hereof.Second Quarter Highlights -- Second quarter revenue increased 30% to $6.5 million from $5.0 million in Q2 2008 -- On a sequential basis, Q2 revenue increased 96% from $3.3 million in Q1 2009 -- Cash and cash equivalents totaled $2.8 million, an increase of 19% from $2.3 million as of March 31, 2009 -- Gross profit increased 80% to $2.7 million from $1.5 million in Q2 2008 -- Sequentially, gross profit increased 121% from 1.2 million in Q1, 2009 -- Gross margins were 42%, up from 30% reported in Q2 2008 and 37% in Q1 2009 -- Net income increased 37% to $1.4 million from $1.0 million in Q2 2008 -- Sequentially, net income experienced a 105% increase from $694,000 in Q1 2009

SOURCE China Kangtai Cactus Biotech Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store